ClinVar Miner

Submissions for variant NM_000284.4(PDHA1):c.899+2T>C

dbSNP: rs2063213491
Minimum review status: Collection method:
Minimum conflict level:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Labcorp Genetics (formerly Invitae), Labcorp RCV003623453 SCV004467508 likely pathogenic Pyruvate dehydrogenase E1-alpha deficiency 2023-05-13 criteria provided, single submitter clinical testing In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. Disruption of this splice site has been observed in individual(s) with pyruvate dehydrogenase complex deficiency (PMID: 33204598). This variant is not present in population databases (gnomAD no frequency). This sequence change affects a donor splice site in intron 9 of the PDHA1 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in PDHA1 are known to be pathogenic (PMID: 10679936, 21914562).

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. The submitted information has not been verified. If you have questions about the information contained on this website, please see a health care professional.